1614. Histoplasmosis in a Non-Endemic Area: An Often Unrecognized Disease
Session: Poster Abstract Session: Mycology - There's a Fungus Among Us: Epidemiology
Friday, October 28, 2016
Room: Poster Hall
  • HistoPoster.pdf (446.0 kB)
  • Background: 

    In non-endemic regions, providers are often unfamiliar with the protean manifestations of histoplasmosis. Consequently, the disease may be overlooked, leading to delays in diagnosis. As pockets of previously unrecognized endemicity are identified and an increasing number of people migrate from high-prevalence areas, it becomes imperative to better characterize histoplasmosis in a traditionally non-endemic region.


    We performed a retrospective chart review of microbiologically or histopathologically-confirmed cases of histoplasmosis at Yale New Haven Hospital in Connecticut from 2005 to 2015. Active histoplasmosis was defined as symptomatic disease. 


    A total of 20 patients were identified. An incidental diagnosis was made in 8 patients after biopsy of asymptomatic pulmonary nodules, most commonly as part of malignancy screening (n=4). Among 12 patients with active histoplasmosis, the mean age was 54 years, 10 were male, 6 were Hispanic and 7 were immunosuppressed (HIV/AIDS =5, HSCT=1, SOT=1).  Eleven patients reported travel to endemic areas (Caribbean in 6). Constitutional symptoms were present in 6. Five patients were admitted to the ICU and 2 developed ARDS. Disseminated histoplasmosis was diagnosed in 8 cases. The most common extrapulmonary sites were the oral mucosa (n=3) and bone marrow (n=3). Histopathology and culture were positive in 11 and 5 cases, respectively. Urine Histoplasma antigen was positive in 6 patients. Eight patients received amphotericin B.  

    Median time to diagnosis from symptom onset and initial evaluation were 41 days (15-226) and 28 days (4-106), respectively. Median time to first Histoplasma antigen testing was 29 days (2-114). Extensive workup (³5 imaging or invasive procedures) was performed in 9 patients while 6 were either discharged or died without diagnosis. Treatment success was achieved in 8 patients; 2 failed treatment and 2 died. 


    The epidemiology of histoplasmosis may differ in non-endemic areas. In this Connecticut series, we noted an elevated prevalence of immunosuppression, particularly HIV/AIDS, and travel to the Caribbean. Failure to recognize the disease may contribute to delayed diagnosis, extensive testing and worse outcomes. Histoplasmosis should be considered in patients presenting with compatible signs and symptoms in a non-endemic area.

    Marwan M. Azar, MD1, Roland Assi, MD, MS2, Onyema Ogbuagu, MD, FACP3, David Peaper, MD, PhD4, Xuchen Zhang, MD, PhD5, Chadi Hage, MD6, L. Joseph Wheat, MD, FIDSA7 and Maricar Malinis, MD, FACP3, (1)Internal Medicine, Infectious Diseases, Yale University, New Haven, CT, (2)Surgery, Yale University, New Haven, CT, (3)Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT, (4)Laboratory Medicine, Yale University School of Medicine, New Haven, CT, (5)Pathology, Yale University, New Haven, CT, (6)Pulmonary-Critical Care Medicine, Thoracic Transplantation Program, Indiana University, Indianapolis, IN, (7)MiraVista Diagnostics, Indianapolis, IN


    M. M. Azar, None

    R. Assi, None

    O. Ogbuagu, None

    D. Peaper, None

    X. Zhang, None

    C. Hage, None

    L. J. Wheat, MiraVista Diagnostics: Owner and director , Owner

    M. Malinis, None

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.